A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline

TRAILRUNNER-ALZ 3 is a clinical trial that is testing if an investigational medicine may help treat people who may have early Alzheimer’s disease or may be at risk for developing symptoms of Alzheimer’s disease.

Researchers think the symptoms of Alzheimer’s disease could be caused by a build-up of amyloid proteins in the brain. These amyloid proteins can stick together and form tiny clumps known as amyloid plaques. Amyloid plaques may lead to problems with memory and thinking.

The investigational medicine being tested in this study may remove amyloid plaques and could delay the time it takes before problems with memory and thinking start or get worse.

Have you noticed changes in your memory or thinking, or are you concerned you may be at risk of Alzheimer’s disease? If so, this trial may be for you. 

You may be able to join the research study if you:

• Are aged 65 to 80 years old
• Have no to mild issues with your memory
• Are willing to obtain a blood test as part of the study that checks whether you have an abnormal protein associated with Alzheimer’s disease
• Have a reliable study partner*

*A study partner is a person who knows you well and would notice any changes in your memory, mood, and behavior. This could be your spouse, partner, friend, family member, or someone whose job it is to help you.

If you qualify to take part in the TRAILRUNNER-ALZ 3 study, you will be randomly assigned to either the investigational medicine group or the placebo group. For every 2 study participants, 1 will get investigational medicine and 1 will get placebo.

This study will last about 5 years. It may include an optional extension to the study treatment period for eligible participants. After the observation period, if the investigational medicine is safe and effective, participants who received placebo may take part in the extension period and get investigational medicine.

Participation is free. The Dementia Centre will cover the costs of procedures that are required as part of the trial.

Participation in this study is voluntary. If you don’t wish to take part, you don’t have to. If you decide to take part and later change your mind, you are free to withdraw from the study at any stage. 

If you are interested in participating please contact Shaun Hopper (details at bottom of page) and for people close to Frankston, please contact 

Xenia Jung, Peninsula Therapeutic and Research Group - Frankston
Mobile: 0491 063 362 or Office: 9770 1579